New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
17:18 EDTPPHMPeregrine trading down 3% after reporting Q2 earnings
News For PPHM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
08:06 EDTPPHMPeregrine reports bavituximab induces immune activation
Peregrine Pharmaceuticals announced the presentation of data from clinical translational studies of the company's phosphatidylserine, or PS,-targeting immunotherapy bavituximab. Initial data from a pilot study of clinical translational ex vivo cultures show that bavituximab, both alone and with docetaxel, elicits evidence of a tumor-specific immune response in patients with human adenocarcinoma of the lung and that bavituximab exhibits an impact on tumors with negative PD-L1 expression. Bavituximab is currently being evaluated in second-line non-small cell lung cancer, or NSCLC, as part of the SUNRISE pivotal Phase III clinical trial.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use